Bin Liu, PhD
Professor, Department of Anesthesia, UCSF
Research Funding
- January 1, 2025 - December 31, 2029 - Targeting tumor-specific epitope for imaging and therapy for mesothelioma , Co-Principal Investigator (MPI) . Sponsor: NIH, Sponsor Award ID: R01CA288612
- June 1, 2024 - May 31, 2029 - Bispecific T cell engager targeting a highly specific tumor cell surface antigen , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA286428
- April 1, 2024 - March 31, 2029 - Develop novel bispecific antibody-drug conjugates against metastatic lethal prostate cancer across subtype , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA289874
- April 1, 2023 - March 31, 2028 - Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors , Co-Principal Investigator (MPI) . Sponsor: NIH, Sponsor Award ID: R01CA280440
- April 15, 2024 - March 31, 2027 - Bispecific antibody-drug conjugates against emerging targets in metastatic lethal prostate cancer , Principal Investigator . Sponsor: DOD, Sponsor Award ID: HT9425-24-1-0341
- June 1, 2018 - May 31, 2023 - Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer , Co-Principal Investigator (MPI) . Sponsor: NIH, Sponsor Award ID: R01CA223767
- August 6, 2012 - July 31, 2019 - Internalizing human antibody-targeted nanosized siRNA therapeutics , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA171315
- March 7, 2006 - March 31, 2016 - Mapping a clinically significant internalizing tumor epitope space , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA118919
- March 1, 2010 - December 31, 2015 - Identifying antigens bound by novel scFvs targeting all subtypes of mesothelioma , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA129491
- February 1, 2009 - January 31, 2012 - Selection of internalizing human antibodies targeting pancreatic tumor cells in s , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R21CA137429
- December 5, 2008 - November 30, 2011 - Internalizing antibody-targeted nanosized siRNA therapeutics , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R21CA135586
- February 1, 2004 - January 31, 2007 - Tumor specific cell sruface epitope- molecular evolution , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R21DK066429
Education
Princeton University, B.A., June 1990, Molecular Biology and Biochemical Sciences University of California, San Francisco, Ph.D., Dec. 1994, Biochemistry and Biophysics
Honors & Awards
- 1990
Summa Cum Laude (Princeton University) - 1990
Phi Beta Kappa (Princeton University) - 1990
Sigma Xi (Princeton University) - 1990
Sigma Xi Book Award (Princeton University) - 1990
E.R. Squibb and Sons Thesis Prize (Princeton University) - 1990
George Khoury '65 Prize For Academic Excellence (Princeton University) - 1990,1991
Regents' Fellow (University of California at San Francisco) - 1994
Chancellor's Fellow (University of California at San Francisco) - 1996-1999
SmithKline Beecham Fellow of the Life Sciences Research Foundation - 1998
Scleroderma Research Foundation investigator award - 2002
American Cancer Society intramural research award - 2002
BioSTAR/UC Discovery award - 2002
CaPCure research award - 2002
DOD New Investigator award - 2004
MARF Investigator award - 2006
MARF Investigator award - 2008
AACR PanCan Pilot award - 2009
UC Discovery SEED award - 2011
MARF Investigator award
Selected Publications
- Su, Y., Zhang, X., Bidlingmaier, S., Behrens, C.R., Lee, N.K., and Liu, B. ALPPL2 is a highly specific and targetable tumor cell surface antigen. Cancer Res., 2020 Aug 31:canres.1418.2020.
View on PubMed - Sherbenou, D.W., Su, Y., Behrens, C.R., Aftab, B.T., Perez de Acha, O., Murnane, M., Bearrows, S.C., Hann, B.C., Wolf, J.L., Martin, T.G., and Liu, B. Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma. Clinical Cancer Res. 2020.
View on PubMed - He, J., Feng, J., Su, Y., Seo, Y., and Liu, B. Quantitative (99m)Tc Labeling Kit for HYNIC-Conjugated Single Chain Antibody Fragments Targeting Malignant Mesothelioma. Bioconjug Chem. 2020 Jul 6.
View on PubMed - Lee, N.K., Su, Y., Bidlingmaier, S., and Liu, B. Manipulation of cell-type selective antibody internalization by a guide-effector bispecific design. Mol Cancer Ther. 2019 Apr 8.
View on PubMed - Su, Y., Bidlingmaier, S., Lee, N.K., Liu, B. Combine Phage Antibody Display Library Selection on Patient Tissue Specimens with Laser Capture Microdissection to Identify Novel Human Antibodies Targeting Clinically Relevant Tumor Antigens. Methods Mol Biol. 2018; 1701:331-347.
View on PubMed - Lee, N.K., Bidlingmaier, S., Su, Y., Liu, B. Modular Construction of Large Non-Immune Human Antibody Phage-Display Libraries from Variable Heavy and Light Chain Gene Cassettes. Methods Mol Biol. 2018; 1701:61-82.
View on PubMed - Lee, N.K., Zhang, Y., Su, Y., Bidlingmaier, S., Sherbenou, D.W., Ha, K.D., Liu, B. Cell-type specific potent Wnt signaling blockade by bispecific antibody. Sci Rep. 2018 Jan 15;8(1):766.
View on PubMed - Su, Y., Liu, Y., Behrens, C.R., Bidlingmaier, S., Lee, N.K., Aggarwal, R., Sherbenou, D.W., Burlingame, A.L., Hann, B.C., Simko, J.P., Premasekharan, G., Paris, P.L., Shuman, M.A., Seo, Y., Small, E.J., and Liu, B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight, 2018 Sept 6;3(17)e121497.
View on PubMed - Ha, K., Bidlingmaier, S., Su, Y., Lee, N.K., Liu, B. Identification of Novel Macropinocytosing Human Antibodies by Phage Display and High-Content Analysis. Methods Enzymol. 2017 585:91-110.
View on PubMed - Bidlingmaier, S., Ha, K., Lee, N.K., Su, Y., Liu, B. Proteome-wide identification of novel ceramide-binding proteins by yeast surface cDNA display and deep sequencing. Mol Cell Proteomics. 2016 Jan 4.
View on PubMed - Ha, K., Bidlingmaier, S., Su, Y., Lee, N.K., Liu, B. Macropinocytosis exploitation by cancers and cancer therapy. Frontier Physiology 2016 sept 12;7:381.
View on PubMed - Sherbenou, D.W., Aftab, B.T., Su, Y., Behrens, C.R., Wiita, A., Logan, A.C., Acosta-Alvear, D., Hann, B.C., Walter, P., Shuman, M.A., Wu, X., Atkinson, J.P., Wolf, J.L., Martin, T.G., Liu, B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 Nov 14.
View on PubMed - Bidlingmaier, S., Su, Y., and Liu, B. Identification of Posttranslational Modification-Dependent Protein Interactions Using Yeast Surface Displayed Human Proteome Libraries. Methods Mol Biol, 2015;1319:193-202.
View on PubMed - Bidlingmaier, S. and Liu, B. Utilizing Yeast Surface Human Proteome Display Libraries to Identify Small Molecule-Protein Interactions. Methods Mol Biol, 2015;1319:203-14.
View on PubMed - Bidlingmaier, S., Liu, B. Combining phage and yeast cell surface antibody display to identify novel cell type-selective internalizing human monoclonal antibodies. Methods Mol Biol, 2015;1319:51-63.
View on PubMed - Bidlingmaier, S., Liu, B. Identification of novel protein-ligand interactions by exon microarray analysis of yeast surface displayed cDNA library selection outputs. Methods Mol Biol, 2015;1319:179-92.
View on PubMed - Ha, K.D., Bidlingmaier, S.M., Zhang, Y., Su, Y., and Liu, B. High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies. Mol Cell Proteomics. 2014 Aug22.
View on PubMed - Sherbenou, D.W., Behrens, C.R. Yang Su, Wolf, J.L., Martin III, T.G., and Liu, B. The Development of Potential Antibody-Based Therapies for Multiple Myeloma. Blood Rev., 2014 Sep 28.
View on PubMed - Behrens, R.C. and Liu, B. Methods for site-specific drug conjugation to antibodies. MAbs, 2013 Sept 27;(6)1: 46-53.
View on PubMed - McCabe, K.E., Liu B., Marks, J.D., Wu., H., and Wu, A. An engineered cysteine-modified diabody for PET imaging of ALCAM-positive pancreatic and colorectal tumor models. Molecular Imaging & Biology. 14(3):336-47 (2012).
View on PubMed